samedan logo
 
 
 
spacer
home > ebr > summer 2004 > a discussion of the ethical issues which surround pharmacogenetics
PUBLICATIONS
European Biopharmaceutical Review

A Discussion of the Ethical Issues which Surround Pharmacogenetics

People often respond differently to the same medicine. Few medicines are effective for everyone and all may cause adverse reactions or even, occasionally, death. Pharmacogenetics, the study of genetic variation between individuals that affects response to medicines, has the potential to play an important role in improving safety and efficacy. Not only do adverse reactions to medicines have significant costs, in both human and monetary terms, but considerable resources are wasted on prescribing medicines that have little or no effect for particular patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Sandy Thomas, Director of the Nuffield Council on Bioethics

Dr Sandy Thomas is Director of the Nuffield Council on Bioethics and Senior Fellow, Science Policy and Technology Research Unit (SPRU) at the University of Sussex. She trained as a Scientist at the University of London (BSc Botany and Zoology, MSc Crop Protection, PhD (Plant Genetics). After lecturing in genetics at the University of London, she became Research Fellow at the Science Policy Research and Technology Unit at the University of Sussex (1987-1997) where she specialised in policy research in life sciences and biotechnology. In 1997, she was appointed as Director of the Nuffield Council on Bioethics through a secondment from the University of Sussex. Over the past decade, she has published widely on the development of public policy for biotechnology, particularly in the area of intellectual property rights and the development and application of genomics. She was a member of the recent UK DFID Commission on Intellectual Property Rights.

spacer
Dr Sandy Thomas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera reinforces its value proposition with a refreshing visual identity

At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement